Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oxford GlycoSciences Plc -- Ignore unavailable to you. Want to Upgrade?

To: Jongmans who wrote (63)	11/14/2000 4:53:24 AM
From: nigel bates	Respond to of 469

From the Guardian this morning - (OGS), yesterday launched a £150m fundraising on the hi-tech US stock market Nasdaq, with plans to double its workforce and take up to 30 new drugs into clinical trials. However, the equity issue was immediately plunged into doubt as the biotech company's shares slumped 302.5p to 2022p amid a general sell-off of technology stocks in the US. The company said unless it could get a minimum price of 2092p for its new shares, it would abandon the fundraising....